ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CFRX
CUSIPN/A
Phone914-207-2300
Debt
Debt-to-Equity RatioN/A
Current Ratio7.52
Quick Ratio7.52
Price-To-Earnings
Trailing P/E Ratio-5.16
Forward P/E Ratio-5.16
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.42 per share
Price / Book4.55
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-15,510,000.00
Net MarginsN/A
Return on Equity-117.29%
Return on Assets-45.55%
Miscellaneous
Employees23
Outstanding Shares79,410,000
Market Cap$154.85 million
ContraFect (NASDAQ:CFRX) Frequently Asked Questions
What is ContraFect's stock symbol?
ContraFect trades on the NASDAQ under the ticker symbol "CFRX."
How were ContraFect's earnings last quarter?
ContraFect Corp (NASDAQ:CFRX) announced its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.17. View ContraFect's Earnings History.
When is ContraFect's next earnings date?
What price target have analysts set for CFRX?
3 brokerages have issued 1-year target prices for ContraFect's stock. Their forecasts range from $2.80 to $2.80. On average, they expect ContraFect's stock price to reach $2.80 in the next twelve months. This suggests a possible upside of 46.6% from the stock's current price. View Analyst Price Targets for ContraFect.
What is the consensus analysts' recommendation for ContraFect?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraFect.
Who are some of ContraFect's key competitors?
Some companies that are related to ContraFect include GlycoMimetics (GLYC), Obseva (OBSV), Kura Oncology (KURA), ChemoCentryx (CCXI), Dova Pharmaceuticals (DOVA), Urogen Pharma (URGN), Basilea Pharmaceutica (BPMUF), Crinetics Pharmaceuticals (CRNX), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS), NuCana (NCNA), TIGENIX/S (TIG), Dermira (DERM), Ra Pharmaceuticals (RARX) and Aduro BioTech (ADRO).
Who are ContraFect's key executives?
ContraFect's management team includes the folowing people:
- Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 65)
- Mr. Michael Messinger, Sr. VP of Fin. & Chief Accounting Officer (Age 43)
- Ms. Nancy Dong, VP of Fin. & Admin. (Age 53)
- Ms. Natalie Bogdanos J.D., Gen. Counsel & Corp. Sec. (Age 49)
- Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 56)
How do I buy shares of ContraFect?
Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ContraFect's stock price today?
One share of CFRX stock can currently be purchased for approximately $1.91.
How big of a company is ContraFect?
ContraFect has a market capitalization of $154.85 million. The biotechnology company earns $-15,510,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. ContraFect employs 23 workers across the globe.
What is ContraFect's official website?
How can I contact ContraFect?
ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]contrafect.com.
MarketBeat Community Rating for ContraFect (NASDAQ CFRX)
MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe CFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
